PUBLISHER: Allied Market Research | PRODUCT CODE: 1179741
PUBLISHER: Allied Market Research | PRODUCT CODE: 1179741
The global conjunctivitis treatment market was valued at $4,213.01 million in 2021, and is projected to reach $6,117.28 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.
Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the "bulbar conjunctiva" which covers the globe and the "tarsal conjunctiva" which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.
Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global conjunctivitis treatment market. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the growth of the conjunctivitis treatment market. Further, different technologies employed in the development of effective treatment boost the market growth.
However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. By drug class, it is classified into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.
By region, North America accounted for the largest market share in the conjunctivitis treatment market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure.
By Drug Class
By Disease Type
By Distribution Channel
By Region